Christopher Wallis, MD, PhD, FRCSC
Christopher Wallis, MD, PhD, FRCSC
Assistant Professor, Division of Urology, University of Toronto
Urologic Oncologist, Division of Urology, Mount Sinai Hospital and University Health Network
Articles by Christopher Wallis, MD, PhD, FRCSC
Drs. Wallis and Sartor highlight issues with the control arm and considerations for treatment sequencing related to PSMAfore.
Drs. Joyce and Wallis consider the impact of financial toxicity and containing costs for patients with GU malignancies.
Drs. Pal and Wallis break down the role of the microbiome and response in patients with kidney cancer.
Dr. Prasad presented the results of the ENVISION trial assessing primary chemoablation in patients with LG-IR NMIBC.
Drs. George and Wallis discuss applications and counseling patients on focal therapy, as well as post-treatment follow-up.
Drs. Faltas and Wallis delve into the genomics of UTUC, including the evolution of disease and FGFR inhibition potential.
Drs. Murray and Wallis discuss optimal patient selection, size criteria, and surgical ablation and chemoablation together.
Drs. Bossi and Wallis conclude with a breakdown of the right patients for radiotherapy when presenting with de novo mCSPC.
Drs. Bossi, Wallis address which patients with mCSPC experience synergistic effects from abiraterone plus radiotherapy.
Drs. Bossi and Wallis break down the results of the PEACE-1 study presented as an LBA at the ASCO Annual Meeting.
ICIs for upper tract disease after upfront chemotherapy, along with the emerging role of targeted therapies.
Approaching perioperative systemic therapy in upper and lower tract disease, including neoadjuvant and adjuvant therapy.
Assessing the treatment landscape in UTUC and how many different patient biomarkers influence treatment integration.
A continuation of the discussion on UTUC vascular-targeted photodynamic therapy as a way of nephron-sparing for patients.
Breaking down the differences in "high risk" and "low risk" stratification in the UTUC guideline, and other biomarkers.
A summary of the therapeutic strategies available for avoiding surgery for UTUC, as well as other management considerations.
Drs. Fizazi and Wallis detail the latest updates regarding TALAPRO-2 for patients with mCRPC and HRR gene alterations.
Drs. Rini and Wallis discuss the results of a late-breaking abstract on KEYNOTE-426, which now has long-term survival data.
The Oncology Brothers chat with Dr. Wallis on PARP inhibitors as well as neoadjuvant IO and EV for bladder cancer.
Drs. Calais, Wallis discuss a post-hoc that showed PSMA PET as effective for treating pelvic, extrapelvic recurrent PC.
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.